Micromet, Inc.
6707 Democracy Boulevard
Suite 505
Bethesda,
MD 20817
United States - Map
Phone: 240-752-1420
Fax: 240-752-1425
Web Site: http://www.micromet.de
| Micromet, Inc., a biopharmaceutical company, engages in the development and sale of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. The companys products under development pipeline using BiTE antibody technology platform include MT103, which is evaluated in a Phase II clinical trial for the treatment of acute lymphoblastic leukemia and in a Phase I clinical trial for the treatment of non-Hodgkins lymphoma; and MT110 that is tested in a Phase I clinical trial for the treatment of patients with solid tumors. Its products also include adecatumumab (MT201), a recombinant human monoclonal antibody in Phase Ib clinical trial to treat patients with metastatic breast cancer; and MT293, a humanized anti-metastatic and anti-angiogenic monoclonal antibody in a Phase I clinical trial for the treatment of patients with solid tumors. In addition, the companys pre-clinical stage products include MT203, a human antibody to treat rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; MT228, a product for melanoma; MT204, a humanized antibody to treat rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis, and multiple sclerosis; MT111 that binds to carcinoembryonic antigen, which is expressed in various solid tumors, including colorectal carcinoma, gastric carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MCSP BiTE antibody to treat melanoma; CD33 BiTE antibody to treat acute myelogenic lymphoma; HER2 BiTE antibody to treat breast cancer; and EGFR BiTE antibody to treat solid tumors. The company has license agreements and collaborations with Biovation Limited; Enzon Pharmaceuticals, Inc.; MedImmune LLC; Merck Serono Biopharmaceuticals S.A.; TRACON Pharmaceuticals, Inc.; Nycomed A/S; Morphotek, Inc.; and Sanofi-Aventis. Micromet, Inc. is headquartered in Bethesda, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Christian Itin Ph.D., 44
Chief Exec. Officer, Pres |
$
545.00K | N/A | Mr. Barclay A. Phillips , 46
Chief Financial Officer, Principal Accounting Officer and Sr. VP |
$
25.00K | N/A | Mr. Patrick A. Baeuerle Ph.D., 51
Chief Scientific Officer, Sr. VP and Member of Exec. Board |
$
450.00K | N/A | Mr. Erich Felber Ph.D., MD, MBA,
Co-Founder |
N/A
| N/A | Dr. Carsten Reinhardt MD, PhD, 42
Chief Medical Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.27% Nasdaq 0.00%
Profile
